ArticleBMC cancer2021

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.

Kristin L Ayers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.